Nucleai is Leading the Spatial Biology Revolution in Precision Medicine
Gaining access to millions of annotated cells across 10+ cancer indications.
Our algorithms detect and characterize tissue and cell architecture.
Cell & area locations are intersected to compute over hundreds of complex feature values.
Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.
Gaining access to millions of annotated cells across 10+ cancer indications.
Our algorithms detect and characterize tissue and cell architecture.
Cell & area locations are intersected to compute over hundreds of complex feature values.
Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.
Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel — August 11, 2026 — Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting […]
TEL AVIV, Israel — July 16th, 2026 — Nucleai, a leader in AI-powered tissue intelligence, today announced expanded access to its multimodal spatial analytics platform, through a partnership with the University of Glasgow’s Spatial Pathology Analytical Research and Clinical Integration (SPARC) Lab. This collaboration extends access to Nucleai’s platform for multiplex image analysis for academic and translational research, providing Glasgow […]
TEL AVIV, Israel–(BUSINESS WIRE)–Nucleai, a leader in AI-powered spatial biology analytics, and Sirona Dx, a Technical CRO, specialized in spatial biology and single-cell services, today announced a strategic partnership to deliver a fully integrated and scalable spatial proteomics solution for pharmaceutical and biotechnology companies. Spatial proteomics platforms are generating increasingly rich and complex tissue […]
Nucleai is a company that uses AI and spatial biology to improve precision medicine and diagnostics by analysing tissue biopsies to predict patient responses to treatments. Avi, tell us briefly about yourself and how Nucleai evolved from supporting oncology drug discovery to focusing on diagnostics within clinical trial settings? I like to describe myself as […]
Tel Aviv, Israel and Glasgow, UK — November 12, 2025 — Nucleai, a leader in AI-powered spatial biology for precision medicine, and the University of Glasgow, a global leader in spatial proteomics and transcriptomics research, today announced a collaboration to identify and validate predictive biomarkers for colorectal cancer (CRC) and advanced polyp incidence. The project […]
Clinical trial data demonstrates how Bio-Techne’s spatial biology technology and Nucleai’s AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne’s COMET™ platform and Nucleai’s multimodal spatial operating system profiled 42 biopsies, revealing immune cell interactions linked to clinical outcomes. Study selected by the scientific committee as one of the […]
